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ABSTRACT
In order to confirm the validity of the Pneumonia Severity Index (PSI) for patients in Europe, data from
adults with pneumonia who were enrolled in two prospective multicentre studies, conducted in France
(Pneumocom-1, n = 925) and Spain (Pneumocom-2, n = 853), were compared with data from the
original North American study (Pneumonia PORT, n = 2287). The primary outcome was 28-day
mortality; secondary outcomes were subsequent hospitalisation for outpatients, and intensive care unit
admission and length of stay for inpatients. All outcomes within individual risk classes, and mortality
rates in low-risk (PSI I–III) and higher-risk patients, were compared across the three cohorts. Overall
mortality rates were 4.7% in Pneumonia PORT, 6.3% in Pneumocom-2 and 10.6% in Pneumocom-1
(p <0.01), ranging from 0.4% to 1.6% (p 0.06) for low-risk patients and from 13.0% to 19.1% (p 0.24) for
high-risk patients. Despite significant differences in baseline patient characteristics, none of the study
outcomes differed within the low-risk classes. The sensitivity and negative predictive value of low-risk
classification for mortality exceeded 93% and 98%, respectively. Thus, in two independent European
cohorts, the PSI predicted patient outcomes accurately and reliably, particularly for low-risk patients.
These findings confirm the validity of the PSI when applied to patients from Europe.
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INTRODUCTION
Community-acquired pneumonia (hereafter
termed pneumonia) is a common infectious dis-
ease with a potentially serious prognosis [1].
Pneumonia is the leading cause of death resulting
from infectious disease in the USA, and the fourth
leading cause of death in the UK [2]. In France
and Spain, the annual incidence of hospitalisation
for pneumonia ranges from 1.5 to 1.8 ⁄ 1000 inhab-
itants, with a case fatality rate of 7.2–9.4% [3,4]
(http://stats.atih.sante.fr/mco/statone.php).
The Pneumonia Severity Index (PSI) was devel-
oped as a clinical prediction tool to identify
pneumonia patients at low risk of short-term
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mortality and other adverse medical outcomes
[5]. In North America, the PSI has been widely
validated as a mortality prediction tool, and its
clinical implementation appears to safely reduce
the hospitalisation rate of low-risk patients with
pneumonia [6–8]. The most recent guidelines for
the management of pneumonia published by the
Infectious Diseases Society of America, the Cana-
dian Infectious Disease Society and the European
Respiratory Society advocate using the PSI (or the
CURB score) to guide the initial treatment setting
for patients with pneumonia [2,9,10]. However,
the PSI has not been validated extensively in
Europe, and its impact on the clinical manage-
ment of patients with pneumonia has not been
widely assessed [11–13]. Previous European stud-
ies to validate the predictive accuracy of the PSI
have been limited by being confined to a single
institution, or by their restriction to more severely
ill patients hospitalised with pneumonia [14–18].
The major goal of the present study was to
validate the accuracy and discriminatory power
of the PSI in predicting the mortality of patients
with pneumonia in two European countries. A
secondary aim was to assess the relationship
between PSI risk class and other clinically rele-
vant patient outcomes. To achieve these aims, the
performance of the PSI in two large multicentre
prospective studies of outpatients and inpatients
with pneumonia, one in France and one in Spain,
was compared to that in the original validation
study performed in the USA (Pneumonia PORT
cohort study) [5].
PATIENTS AND METHODS
Design
This external validation of the PSI was based on data obtained
from two prospective, multicentre studies of adults with
pneumonia performed in France and Spain (i.e., Pneumocom-1
and Pneumocom-2, respectively) and from the original North
American study (i.e., the Pneumonia Patient Outcomes
Research Team (PORT) cohort study) which served to validate
the PSI [5]. The study methods used for the Pneumonia PORT
and Pneumocom-1 studies have been reported previously
[5,13].
The Pneumonia PORT cohort and the Pneumocom-1 stud-
ies included 2287 patients and 925 patients in five North
American centres and 16 French emergency departments
(EDs), respectively. Pneumocom-2 was a registry of commu-
nity-acquired pneumonia in EDs located in Catalonia, Spain.
Fourteen EDs with > 10 000 patients ⁄ year participated in
Pneumocom-2 on a voluntary basis. Taken together, the 14
EDs in Pneumocom-2 dealt with c. 680 000 patients ⁄ year. Five
of the EDs participating in Pneumocom-2 were university-
affiliated, and five treated >40 000 patients ⁄ year. Local inves-
tigators conducted follow-up telephone interviews with the
patient, a relative or the family practitioner at least 28 days
after presentation. Follow-up hospital data were collected
using a structured review of medical records covering the first
28 days after admission. During the study monitoring period,
baseline chest radiographs and completed data collection
forms were reviewed and checked for accuracy by the study
investigator (E.C.). The study protocol was approved by the
institutional review board at each centre.
Table 1 compares the methodological characteristics and
eligibility criteria of these three prospective, multicentre,
observational inception cohort studies. All studies enrolled
consecutive consenting adults with a clinical and radio-
graphical diagnosis of pneumonia. Patients who were infected
with human immunodeficiency virus, and those patients likely
to have healthcare-associated pneumonia, were excluded from
all three cohorts. Unlike the PORT cohort, both of the
European cohorts excluded immunosuppressed patients, and
the Pneumocom-1 study excluded patients with a history of
cystic fibrosis, as well as patients who were ventilated via a
tracheotomy or by prolonged mechanical ventilation.
Baseline data collection
All studies used interviews and a standardised review of
medical records to collect baseline data, including: (i) demo-
graphical factors; (ii) co-morbid illnesses included and not
included in the PSI; (iii) physical examination findings; (iv)
results of laboratory tests that were performed at the discretion
of the managing physician; and (v) radiographical findings.
Table 1. Comparison of study design and patient eligibil-
ity criteria across study populations
Study characteristics
Pneumonia
PORT Pneumocom-1 Pneumocom-2
Enrolment period 10 ⁄ 1991
to 03 ⁄ 1994
02 ⁄ 2002
to 07 ⁄ 2003
01 ⁄ 2003
to 12 ⁄ 2003
Number of study sites 5 16 14
Country USA and
Canada
France Spain
Inclusion criteria
Age ‡18 years Yes Yes Yes
Clinical diagnosis of
pneumonia
Yes Yes Yes
New radiographical pulmonary
infiltrate
Yes Yes Yes
Provision of informed consent Yes Yes Yes
Exclusion criteria
Hospital discharge within
7–10 days before presentationa
Yes Yes Yes
Positive HIV antibody titre Yes Yes Yes
Immunosuppressionb – Yesc Yesc
History of cystic fibrosis – Yesd –
Ventilated via a tracheotomy
or prolonged mechanical
ventilation
– Yesd –
aSeven days for the Pneumocom-1 and Pneumocom-2 studies; 10 days for the
Pneumonia PORT study.
bImmunosuppression was defined as either: (i) active cancer, leukaemia, or
lymphoma; (ii) white blood cell count <3000 ⁄mm3 or an absolute neutrophil count
<1000 ⁄mm3 on presentation; (iii) asplenia, anatomical or functional; (iv) hypogam-
maglobulinaemia; (v) immunosuppressive or myelosuppressive drug therapy
within the 30-day period preceding presentation; (vi) documentation of patient
‘on chemotherapy’; or (vii) radiation therapy.
cImmunosuppression was present in 72 (22.2% of exclusions) and ten (9.6%)
patients not included in Pneumocom-1 and Pneumocom-2, respectively.
dOne patient with cystic fibrosis and six patients ventilated with a tracheotomy
were excluded from Pneumocom-1.
HIV, human immunodeficiency virus.
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The PSI risk score and risk class for each patient were
calculated using the methods described in the original valid-
ation of the PSI [5]. In particular, for all of the dichotomous
variables included in the PSI, missing values were assumed to
be normal (as was assumed in the original derivation and
validation cohorts of the PSI) [5,19]. Patients in risk classes I–III
were defined as low-risk, and those in risk classes IV or V as
high-risk [5]. Consistent with previous definitions, enrolled
patients who were treated initially in an ambulatory setting,
including those who were admitted subsequently to a hospital,
were classified as outpatients. All patients admitted to a
hospital following presentation at a participating ED were
classified as inpatients [20].
Assessment of outcomes
All-cause mortality was assessed at 30 days, except in Pneum-
ocom-1, which assessed 28-day all-cause mortality. For con-
sistency, 28-day all-cause mortality was therefore used as the
primary study outcome for all three studies. Secondary
outcomes were: subsequent hospitalisation for outpatients;
direct admission to an intensive care unit (ICU) for inpatients
(i.e., inpatients admitted to the ICU in the first few hours after
arrival at the ED); and length of stay for inpatients discharged
from hospital.
Statistical analyses
Baseline patient characteristics, mortality rates, subsequent
hospitalisation for outpatients and direct admission to an ICU
were compared across study populations using chi-square
statistics or Fisher’s exact tests, as appropriate. Length of stay
for discharged inpatients was censored at 28 days and ana-
lysed using discrete proportional odds models for grouped
time-to-event data. The Mantel–Haenszel chi-square test for
trend was used to assess the associations between increasing
risk class and the rates of the categorical secondary outcomes.
Lengths of stay for discharged inpatients were analysed using
a test of trend for survival functions, stratified by PSI risk class
and study cohort. The area under a receiver operator charac-
teristic curve (AUC) was used to assess the overall discrim-
inatory power of the PSI to predict mortality in the two
European cohorts, as compared with the Pneumonia PORT
cohort. For all analyses, a two-tailed p value of <0.05 was used
to define statistical significance.
In order to assess the accuracy of the PSI in predicting
28-day all-cause mortality, the sensitivity, specificity, positive
and negative predictive values, and positive and negative
likelihood ratios for low-risk vs. high-risk patients, were
compared across the three study populations [21,22]. Statistical
analyses were performed using Stata v.8.0 (Stata Corporation,
College Station, TX, USA).
RESULTS
Pneumocom-2 enrolled 939 patients who ful-
filled all inclusion criteria, although 86 were
subsequently excluded because of post-hoc find-
Table 2. Comparison of baseline
patient characteristics across study
populations
Patient characteristics
Pneumonia PORT
(n = 2287)
Pneumocom-1
(n = 925)
Pneumocom-2
(n = 853) p value
Demographical factors (%)
Age <51 years 42.7 24.3 26.0 <0.01
Female gender 50.0 36.2 37.4 <0.01
Nursing home residence 8.5 12.4 7.4 <0.01
Coexisting conditions (%)
Cancer 5.8 7.3 6.4 0.26
Cerebrovascular disease 9.2 10.2 6.7 <0.03
Congestive heart failure 11.1 16.3 15.4 <0.01
Coronary artery disease 17.7 14.3 11.7 <0.01
Pulmonary disease 17.6 16.1 30.8 <0.01
Renal disease 6.7 4.9 4.4 0.02
Liver disease 1.4 1.8 4.1 <0.01
Diabetes mellitus 10.3 10.7 15.7 <0.01
Physical examination findings (%)
Altered mental status 10.4 8.0 11.0 <0.06
Respiratory rate ‡30 ⁄min 13.3 25.0 24.1 <0.01
Systolic blood pressure <90 mmHg 2.1 3.2 2.1 0.15
Temperature <35 or ‡40C 1.5 6.7 0.8 <0.01
Heart rate ‡125 ⁄min 8.7 9.8 8.2 0.45
Laboratory and radiographical findings (%)
Arterial pH <7.35 3.7 4.6 4.4 <0.36
Blood urea nitrogen ‡11 mmol ⁄L (30 mg ⁄dL) 14.2 18.4 28.0 <0.01
Sodium <130 mmol ⁄L 3.9 7.5 2.9 <0.01
Glucose ‡14 mmol ⁄L (250 mg ⁄dL) 4.1 5.9 7.8 <0.01
Haematocrit <0.30 6.3 6.9 3.5 <0.01
Oxygen desaturationa 20.6 39.8 37.7 <0.01
Pleural effusion 8.9 14.0 4.6 <0.01
PSI risk class (%)
Class I 33.8 16.5 20.5
Class II 20.9 13.9 15.9
Class III 14.2 18.0 17.5
Class IV 21.2 35.3 28.5
Class V 9.9 16.1 17.6
All low-risk classes (I–III) combined 68.9 48.5 53.9 <0.01
Initial treatment as outpatient 41.3 17.7 33.6 <0.01
aOxygen desaturation was defined as a PaO2 <60 mmHg via blood gas analysis or an oxygen saturation via pulse
oxymetry of <90%; both either on room air or with supplementary oxygen therapy.
PSI, Pneumonia Severity Index.
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ing of an exclusion criterion (n = 40) or assign-
ment of a final diagnosis other than pneumonia
(n = 46). Overall, 1778 patients were enrolled in
the two European cohorts (925 in the French
Pneumocom-1 study and 853 in the Spanish
Pneumocom-2 study), and 2287 patients were
enrolled in the Pneumonia PORT cohort study
(Table 2).
Compared to patients in the PORT cohort
study, the two European cohorts were older
(mean age 66 and 65 years vs. 56 years) and a
greater proportion were male (63.8% and 62.6%
vs. 50.0%). Given large differences in most prog-
nostic variables included in the PSI across study
populations, only c. 50% of the patients enrolled
in Pneumocom-1 and Pneumocom-2 were low-
risk (PSI risk classes I–III), compared with > 66%
of the patients enrolled in the PORT cohort. The
proportion of patients treated in the outpatient
setting ranged from 17.7% in Pneumocom-1 to
33.6% in Pneumocom-2, as compared with 41.3%
in the PORT cohort (p <0.01).
Association of PSI risk class and mortality
across study populations
Overall 28-day mortality differed significantly
between the two European cohorts and Pneu-
monia PORT, from 10.6% in Pneumocom-1 and
6.3% in Pneumocom-2, to 4.7% in the PORT
cohort (p <0.01); this was explained by higher
Fig. 1. Receiver operating characteristic (ROC) curves of
the Pneumonia Severity Index (PSI) for the PORT study
and the two European cohorts. The ROC curves plot the
sensitivity (y axis) vs. 1-specificity (x axis) of the PSI score
to predict 28-day all-cause mortality. The area under the
ROC curve (AUC) quantifies the overall discriminatory
power of the PSI for predicting mortality. The AUCs
differed across the three study populations (p <0.01) and
were largest for the Pneumonia PORT and Pneumocom-2
populations, and smallest for the Pneumocom-1 population.
Table 3. Comparison of mortality,
grouped by Pneumonia Severity
Index (PSI) risk class, for outpatients
and inpatients across study popula-
tionsTreatment setting
Pneumonia
PORT Pneumocom-1 Pneumocom-2
Pneumocom-1
and -2
p valuea
Patients
n
Death
%
Patients
n
Death
%
Patients
n
Death
%
Patients
n
Death
%
Outpatient only
Class I 587 – 84 – 128 – 212 – –
Class II 244 0.4 50 – 75 – 125 – 1.00
Class III 72 – 14 – 43 – 57 – –
Low risk 903 0.1 148 – 246 – 394 – 1.00
Class IV 40 12.5 12 16.7 31 – 43 4.7 0.25
Class V 1 – 4 50.0 10 10.0 14 21.4 1.00
High-risk 41 12.2 16b 25.0 41 2.4 57 8.8 0.58
All outpatients 944 0.6 164 2.4 287 0.3 451 1.1 0.34
Inpatient only
Class I 185 – 69 – 47 – 116 – –
Class II 233 0.9 79 1.3 61 1.6 140 1.4 0.63
Class III 254 1.2 153 3.9 106 1.9 259 3.1 0.14
Low-risk 672 0.7 301 2.3 214 1.4 515 1.9 0.07
Class IV 446 8.7 315 10.8 212 3.8 527 8.0 0.82
Class V 225 25.3 145 36.5 140 30.0 285 33.3 0.05
High-risk 671 14.3 460c 18.9 352 14.2 812 16.9 0.18
All inpatients 1343 7.5 761 12.3 566 9.4 1327 11.1 <0.01
Outpatients and
inpatients combined
Class I 772 – 153 – 175 – 328 – –
Class II 477 0.6 129 0.8 136 0.7 265 0.8 1.00
Class III 326 0.9 167 3.6 149 1.3 316 2.5 0.08
Low-risk 1575 0.4 449d 1.6 460 0.6 909 1.1 0.06
Class IV 486 9.0 327 11.0 243 3.3 570 7.7 0.58
Class V 226 25.2 149 36.9 150 28.7 299 32.8 0.07
High-risk 712 14.2 476d,e 19.1 393 13.0 869 16.3 0.24
All patients 2281 4.7 925 10.6 853 6.3 1778 8.5 0.01
aEuropean (Pneumocom-1 and -2) studies vs. Pneumonia PORT.
bp 0.02 (Pneumocom-1 vs. Pneumocom-2), p 0.23 (Pneumocom-1 vs. Pneumonia PORT).
cp 0.09 (Pneumocom-1 vs. Pneumocom-2).
dp 0.05 (Pneumocom-1 vs. Pneumonia PORT).
ep 0.02 (Pneumocom-1 vs. Pneumocom-2).
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mortality among inpatients from the European
cohorts (147 ⁄ 1327 vs. 101 ⁄ 1343, p 0.002). Mortal-
ity ranged from 0.4% to 1.6% (p 0.06) for low-risk
patients, and from 13.0% to 19.1% (p 0.24) for
high-risk patients. After stratification by site of
treatment (outpatient vs. inpatient) and severity
of illness (low-risk vs. high-risk), mortality rates
did not differ significantly among the three study
cohorts (Table 3).
The discriminatory power of the PSI in pre-
dicting mortality was excellent for the two cohorts
from Europe (both ‡0.85; Fig. 1). There was no
significant difference in the AUCs between
Pneumocom-2 and the PORT cohort (p 0.91);
however, the AUC was significantly smaller for
Pneumocom-1 than for the PORT cohort (p 0.05).
The accuracy of the PSI in predicting mortality
at the predefined threshold for low-risk and high-
risk patients is shown in Table 4. The sensitivity
of the PSI was 93–94%, its negative predictive
value was ‡98%, and the negative likelihood
ratios were consistently low (0.1–0.3) in all three
study cohorts.
Association of PSI risk class and secondary
outcomes across study populations
There were significant trends (p <0.01) in line
with increasing risk class for all three study
populations in terms of an increasing subsequent
hospitalisation rate of outpatients, ICU admission
for inpatients, and length of hospital stay for
Table 5. Comparison of secondary
outcomes, grouped according to
Pneumonia Severity Index (PSI) risk
class, across study populations
Outcome by site of treatment Pneumonia PORT Pneumocom-1 Pneumocom-2 p valuea
Subsequent hospitalisation
of outpatients, n (%)b
Class I 587 (5.3) 84 (4.8) 128 (4.7) 1.00
Class II 244 (8.2) 50 (16.0) 75 (6.7) 0.19
Class III 72 (16.7) 14 (14.3) 43 (7.0) 0.31
Class IV 40 (20.0) 12 (25.0) 31 (16.1) 0.75
Class V 1 (0.0) 4 (25.0) 10 (30.0) 0.80
All outpatients 944 (7.5) 164 (11.0) 281 (7.7) 0.31
p valuec <0.01 <0.01 <0.01
ICU admission of
inpatients, n (%)b
Class I 185 (2.2) 69 (4.3) 47 (2.1) 0.52
Class II 233 (3.4) 79 (7.6) 61 (4.9) 0.27
Class III 254 (5.1) 153 (6.5) 106 (3.8) 0.66
Class IV 446 (7.4) 315 (11.1) 212 (1.4) <0.01
Class V 225 (19.6) 145 (17.9) 140 (7.1) <0.01
All inpatients 1343 (7.6) 761 (10.5) 566 (3.7) <0.01
p valuec <0.01 <0.01 <0.01
Length of stay for inpatients
discharged alive, median days
(inter-quartile range)b
Class I 5 (5,11) 7 (6,11) 5 (4,10) <0.03
Class II 6 (4,9) 7 (5,9) 7 (5,11) 0.83
Class III 7 (5,11) 12 (8,17) 7 (5,11) <0.01
Class IV 9 (6,15) 12 (8,20) 8 (6,11) <0.01
Class V 10 (7,16) 16 (9,28) 9 (6,12) <0.01
All inpatients discharged alive 7 (5,12) 11 (7,18) 8 (5,11) <0.01
p valuec <0.01 <0.01 <0.01
aEstimation of these p values was based on a comparison of proportions across study populations within a given
risk class for the outcomes ‘subsequent hospitalisation of outpatients’ and ‘ICU admission of inpatients’. Length of
stay was based on discrete proportional odds models for grouped time-to-event data.
bDenotes the number of outpatients or inpatients in a particular PSI risk class for a given outcome.% represents the
proportion of outpatients or inpatients in a given PSI risk class with the specified outcome.
cEstimation of these p values was based on a test for trend in proportions across the five PSI risk classes for
subsequent hospitalisation of outpatients and ICU admission of inpatients. For length of stay, the estimation was
based on a test of trend of survivor functions across the five PSI risk classes.
Table 4. Comparison of the accu-
racy of the Pneumonia Severity
Index (PSI) in predicting mortality
across study populations Accuracy measurea
Parameter (95% CI)
PORT
(n = 2287)
Pneumocom-1
(n = 925)
Pneumocom-2
(n = 853)
Sensitivity (%) 94.4 (88.2–97.9) 92.9 (95.8–97.1) 94.4 (84.6–98.8)
Specificity (%) 71.8 (69.9–73.7) 53.2 (49.7–56.6) 57.1 (53.6–60.5)
Positive predictive value (%) 14.1 (11.7–16.9) 19.0 (15.6–22.8) 12.9 (9.8–16.7)
Negative predictive value (%) 100 (99.2–99.9) 98.4 (96.8–99.4) 99.3 (98.1–99.9)
Positive likelihood ratio 3.4 (3.1–3.6) 2.0 (1.8–2.2) 2.2 (2.0–2.4)
Negative likelihood ratio 0.1 (0.0–0.2) 0.1 (0.1–0.3) 0.1 (0.0–0.3)
aThe accuracy measure of the test was based on the categorisation of patients as low-risk (PSI risk classes I–III) and
high-risk (PSI risk classes IV–V) for 28-day all-cause mortality.
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discharged inpatients (Table 5). Subsequent hos-
pitalisation of outpatients did not differ among
the two European cohorts and the PORT cohort
within any risk class (I–V). ICU admission rates of
inpatients in low-risk classes (I–III) did not differ
among the two European cohorts and the PORT
cohort; however, there were significant differ-
ences in ICU admission rates of inpatients in risk
classes IV and V. With the exception of risk class
II, there were significant differences in length of
stay across study populations within all risk
classes. Length of stay was highest in Pneumo-
com-1 within each risk class, while length of stay
was similar in Pneumocom-2 and the Pneumonia
PORT studies.
DISCUSSION
This study, conducted in two European countries,
provides external validation of the reliability of
the PSI for identifying low-risk patients with
pneumonia, and further supports its clinical use
for risk stratification and as a decision-making tool
in settings beyond North America [6–8,12].
Indeed, a trial conducted recently in Spain found
no differences in mortality or other clinical out-
comes among low-risk patients (PSI risk class II or
III) who were allocated randomly to inpatient or
outpatient treatment [12]. Three previous inter-
ventional studies conducted in North America,
and one conducted in Spain, have demonstrated
the effectiveness and safety of implementing the
PSI to guide the initial treatment setting for
patients with pneumonia [6–8,11]. The present
study provides supporting evidence for the gen-
eral applicability of the PSI, almost 10 years after
its original North American validation, within
different healthcare systems.
Consistent with previous studies from North
America and Europe, the overall mortality rate for
low-risk patients (PSI risk classes I–III) was £0.1%
for outpatients and £2.3% for inpatients in both
cohorts from Europe [6,8,15,23,24]. Mortality rates
did not differ among low-risk outpatients and
inpatients within risk classes between the two
external validation cohorts and the Pneumonia
PORT cohort, thereby further establishing the
reliability of the PSI in identifying low-risk
patients [25]. Accordingly, the negative predictive
value of the PSI was very high (‡98%) for all three
study populations, a finding that supports the
management of low-risk patients from Europe in
the outpatient setting. However, the difference
in mortality rates between outpatients and in-
patients within low-risk and high-risk categories
highlights the fact that some low-risk patients
have specific physiological and social needs that
are not taken into account by the PSI and that
make them candidates for hospital admission.
This suggests that physicians dealing with emer-
gencies can use the PSI as a guide for their
decision concerning hospitalisation, but should
not base this decision exclusively upon the PSI
classification.
The specificity and positive predictive values of
the PSI were lower than its sensitivity and
negative predictive values because of the low
mortality rates in all three study populations, and
probably also because the PSI was designed to
identify patients at low risk of mortality. In the
two European cohorts, mortality rates among
high-risk patients ranged from 2.4% to 25% for
outpatients, and from 14.2% to 18.9% for in-
patients, compared to 12.2% and 14.3%, respect-
ively, in the PORT cohort (Table 3).
The possibility that population differences in
the distributions of PSI risk scores within risk
class could explain the observed variation in
mortality rates was not supported by the analysis.
As an alternative, population differences in the
distribution of co-morbid conditions within high-
risk patients could account for the differences. For
example, risk class IV patients in Pneumocom-2
had a lower prevalence of cerebrovascular and
renal disease than those in the other two cohorts,
which may account, in part, for the low mortality
rate in this risk class. Conversely, the same study
population also had a substantially higher pre-
valence of chronic pulmonary disease. Therefore,
it is possible that chronic pulmonary illness led to
greater derangements in respiratory physiology,
which in turn resulted in an overestimation of the
mortality risk for these patients. In addition, the
possibility that an unknown patient characteristic
or unmeasured process of care across study
populations confounded the relationship between
risk class and mortality cannot be excluded.
Finally, these variations were recorded across
small subgroups and for a small number of
events, and although mortality rates differed
significantly across the three cohorts, there was
no difference in overall mortality rates among
high-risk patients between the two European
cohorts and the PORT cohort (Table 3).
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As shown in Table 4, sensitivity and specificity
were slightly lower within Pneumocom-1, and
accordingly, the AUC of Pneumocom-1 was
slightly, but significantly, lower than those of
Pneumonia PORT and Pneumocom-2. Indeed,
predicted short-term mortality was slightly less
accurate for patients in intermediate risk classes
in Pneumocom-1 (Fig. 1), and the mortality rate
for such patients was somewhat higher; never-
theless, absolute differences in mortality rates
were quite small (Table 3). Differences in study
population characteristics and patterns of medical
practice might explain such differences; however,
since the studies did not collect these data in a
standardised fashion, it was not possible to
include these differences in the analysis. As the
PSI was designed originally to identify low-risk
patients, and it is presumed that most high-risk
patients will be hospitalised, these differences in
mortality rates among high-risk patients do not
negate the utility of the PSI as a tool for triaging
low-risk patients with pneumonia [5].
The observed relationships between risk class
and the secondary study outcomes further sup-
port the robustness of the PSI as a prediction tool
for the prognosis of patients with pneumonia.
The rates of subsequent admission of outpa-
tients, and of ICU admission of inpatients,
increased significantly with increasing risk class
across all study populations (Table 5). In addi-
tion, rates of subsequent hospitalisation of out-
patients within all risk classes, and of ICU
admission of inpatients within low-risk classes,
were similar among the European and the North
American cohorts. In contrast, length of stay for
specific risk classes varied widely by study
population, with the longest stays observed in
Pneumocom-1. Differences in patterns of medical
practice and methods of healthcare financing
among countries could account, in part, for these
differences in length of stay [26–28]. The differ-
ences in study population characteristics noted
above might also result in different lengths of
stay, particularly in relation to the shorter length
of stay observed in Pneumocom-2 as compared
to Pneumocom-1. Finally, the overall lower rate
of outpatient treatment in Pneumocom-1 might
be explained by the higher proportion of low-
risk patients, especially within the Pneumonia
PORT cohort, and by differences in patterns of
medical practice and in study population char-
acteristics.
PSI is not the only tool available for predicting
mortality and other adverse outcomes for
patients with pneumonia, and alternative
prediction tools such as the CURB, CURB-65
and CRB-65 have been proposed [29,30] The
latter prediction tools have been validated
prospectively in various settings, particularly in
Europe, where they were originally designed
[31]. The overall discriminatory power for all of
these prediction tools was close. In a study
conducted with a large North American cohort,
Aujesky et al. [19] showed that PSI performed
slightly better than CURB and CURB-65, while
Capelastegui et al. [31] found an equivalence of
the predictions made by the PSI, the CURB-65
and the CRB-65 score in a large single-centre
Spanish cohort. Given that the CURB-65 and,
particularly, the CRB-65 scores are simpler than
the PSI, some studies have advocated their use in
non-specialised hospital settings [32].
The present study has several limitations
that must be acknowledged. First, there were
obvious differences among the three cohorts
analysed. Although all were prospective, multi-
centre studies, and comparable numbers of
patients were included in the two European
cohorts and the original validation PORT cohort,
each study had a distinctive design and data
collection method; additionally, Pneumocom-1
and Pneumocom-2 enrolled patients a decade
later than the Pneumonia PORT cohort [21,25].
Differences recorded in patient characteristics
could therefore reflect differences in variable
definitions used across study populations rather
than true differences; however, the definitions
used in Pneumocom-1 and Pneumocom-2 were
all based on the Pneumonia PORT study, making
this hypothesis unlikely. Second, the present
findings were based solely upon patient charac-
teristics, and therefore do not take into account
processes of care (e.g., collection of blood cul-
tures or time to initiation and appropriateness of
antimicrobial therapy) or causative pathogens,
which may have confounded the relationships
among study populations, risk classes and
patient outcomes. Since the studies did not
collect these data in a standardised fashion, it
was not possible to adjust for such processes of
care or aetiological agents in the present analysis.
In conclusion, this external validation of the PSI
in two geographically distinct European cohorts,
almost 10 years after the original North American
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validation, confirms that this prognostic tool for
pneumonia retains a high discriminatory power
that provides an accurate and reliable prediction
of the risk of mortality and other adverse out-
comes, particularly within the low-risk subgroup
of patients (i.e., risk classes I–III). These findings
confirm the general applicability of this tool,
following its design and initial validation in North
America, to EDs in Europe, and support the
implementation of this tool to guide the initial
choice of treatment setting for low-risk patients
with pneumonia [12].
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